GlassScriptPhysician profile
Anthony Ippolito
NPI 1801012372
$705.68
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $92.74 · 2021: $82.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $104.76 | 2019-2020 | |
| Lilly USA, LLC | $95.96 | 2019-2021 | |
| Genentech USA, INC. | $64.01 | 2019 | |
| Amgen INC. | $63.28 | 2019 | |
| Pfizer INC. | $60.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.45 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $48.08 | 2019-2020 | |
| Gilead Sciences, INC. | $37.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.43 | 2021 | |
| Abbvie INC. | $30.88 | 2019-2020 | |
| Ucb, INC. | $28.02 | 2019 | |
| Janssen Biotech, INC. | $25.09 | 2021 | |
| Radius Health, INC. | $17.15 | 2019 | |
| Genzyme Corporation | $16.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ippolito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.